Researchers may have found a group of immune cells that increase in number with age but are too worn out to fight diseases. The accumulation of dysfunctional virtual memory T cells, in addition to the loss of true naïve T cells this may explain why older people have reduced immune responses to cancer and vaccines, why cancer immunotherapy is less successful in the elderly, and may help to tailor cancer immunotherapy treatments specifically for older patients.
The increased incidence of cancer with ageing, combined with the rapidly ageing population is called the Silver Tsunami.A new study out of Monash University, may have found a group of immune cells that increase in number with age but are too worn out to fight off diseases.
Professor Nicole La Gruta and Dr Kylie Quinn, from Monash University's Biomedicine Discovery Institute, have found that a subset of immune cells, called virtual memory T cells, make up around 5% of T cells in young animal models and humans but accumulate significantly with old age and lose the ability to become activated. Importantly, the Monash researchers found that another subset, called true naïve T cells, retain their capacity to mount an immune response but decline in frequency dramatically with increasing age, from 90 per cent to 30 per cent in animal models and humans. These shifts are likely caused by age-related inflammation or "inflamm-ageing."
"In cancer immunotherapy, a patient's own T cells are stimulated to kill cancer cells and it has been hugely successful for certain forms of cancer. Unfortunately, older patients or people over 65 years of age respond less well than younger ones.This may be because of the differences we see in these T cell subsets in older versus younger patients.Now that we understand the impact of ageing on these T cells, we may be able to selectively target them to improve this cutting edge cancer treatment." Professor La Gruta said.
According to Prof La Gruta and Dr Quinn, this may mean developing treatments to remove dysfunctional virtual memory T cells or enrich for functional true naïve T cells during cancer immunotherapy or developing treatments that reduce chronic inflammation to prevent immune decline.
"Using these observations, we may be able to tailor cancer immunotherapy specifically for the needs of an older patient's immune system- this is where medicine must head to meet the needs of our ageing society" Professor La Gruta said.
Overall, for older Australians, lung cancer is the most common cause of death from cancer, followed by prostate, colorectal, pancreatic, and breast cancer (women).
Submit your Abstract on Track : Anti-Aging Medicine and Cancer Treatment: Click Here